Lexeo Therapeutics (LXEO) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palisade Bio (PALI) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 27.5% versus a loss of 60.0%. Lexeo Therapeutics is the larger company by market cap ($263.5 million vs $252.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXEO | PALI |
|---|---|---|
| Share price | $3.21 | $1.45 |
| Market cap | $263.50M | $252.69M |
| 1-day change | -3.02% | -2.03% |
| YTD return | -67.67% | -38.30% |
| 1-year return | -60.02% | -27.50% |
| 5-year return | — | -99.93% |
| P/E ratio (TTM) | — | 2.42 |
| EPS (TTM) | $-1.02 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.99 | $2.86 |
| 52-week low | $2.98 | $1.32 |
| Distance from 52-week high | -70.79% | -49.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +532.40% | +604.83% |
| Average volume | 1.20M | 2.56M |
| Shares outstanding | 82.09M | 174.27M |
| Employees | 63 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PALI has outperformed LXEO by 32.5 percentage points over the past year.
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
LXEO vs PALI FAQ
Which is bigger, Lexeo Therapeutics or Palisade Bio?
Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $263.50M compared with $252.69M for Palisade Bio (PALI).
Which stock has performed better over the past year, LXEO or PALI?
PALI returned -27.50% over the past 12 months, compared with -60.02% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Lexeo Therapeutics and Palisade Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.